acetaminophen has been researched along with Muscular Dystrophy in 3 studies
Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.
paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The dosage of paracetamol ingested was within current guidance yet there was sudden derangement of liver function." | 1.56 | Normal dose paracetamol in muscular dystrophy patients - is it normal? ( Philipose, Z; Teo, KS; Yin, JL, 2020) |
| "We determined acetaminophen protein adduct levels, in combination with a literature review and systematic evaluation of the cases, using the Roussel Uclaf Causality Assessment Method for drug-induced liver injury to assess causality between recommended acetaminophen dosing and acute liver failure in two children with myopathies." | 1.37 | Acute liver failure after recommended doses of acetaminophen in patients with myopathies. ( Ceelie, I; de Wildt, SN; Gijsen, V; Ito, S; James, LP; Koren, G; Mathot, RA; Tesselaar, CD; Tibboel, D, 2011) |
| "We report two cases of fulminant hepatic failure caused by therapeutic (4 g x day(-1)) paracetamol administration on our Intensive Care Unit." | 1.35 | Acute liver failure following therapeutic paracetamol administration in patients with muscular dystrophies. ( Grant, IS; Pearce, B, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Yin, JL | 1 |
| Teo, KS | 1 |
| Philipose, Z | 1 |
| Ceelie, I | 1 |
| James, LP | 1 |
| Gijsen, V | 1 |
| Mathot, RA | 1 |
| Ito, S | 1 |
| Tesselaar, CD | 1 |
| Tibboel, D | 1 |
| Koren, G | 1 |
| de Wildt, SN | 1 |
| Pearce, B | 1 |
| Grant, IS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetics and Safety of Treatment With Paracetamol in Children and Adults With Spinal Muscular Atrophy and Cerebral Palsy[NCT03648658] | Phase 4 | 48 participants (Anticipated) | Interventional | 2019-02-18 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for acetaminophen and Muscular Dystrophy
| Article | Year |
|---|---|
Normal dose paracetamol in muscular dystrophy patients - is it normal?
Topics: Acetaminophen; Adolescent; Alanine Transaminase; Analgesics, Non-Narcotic; Humans; Liver; Male; Musc | 2020 |
Acute liver failure after recommended doses of acetaminophen in patients with myopathies.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Child; Female; Humans; Intensive Care Units, Pe | 2011 |
Acute liver failure following therapeutic paracetamol administration in patients with muscular dystrophies.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Humans; Liver Failure, Acute; Male; Muscular Dystrop | 2008 |